JP Morgan Chase
ALXN

JP Morgan Chase’s Alexion Pharmaceuticals ALXN Stock Holding History

JP Morgan Chase’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-339,100
Closed -$62.3M – 7067
2021
Q2 		$62.3M Buy
339,100
+275,000
+429% +$47.2M 0.01% 1112
2021
Q1 		$9.8M Sell
64,100
-45,500
-42% -$7.04M ﹤0.01% 2380
2020
Q4 		$17.1M Hold
109,600
– – ﹤0.01% 1752
2020
Q3 		$12.3M Sell
109,600
-27,400
-20% -$2.96M ﹤0.01% 1876
2020
Q2 		$15.4M Buy
137,000
+47,800
+54% +$5.07M ﹤0.01% 1561
2020
Q1 		$8.01M Sell
89,200
-123,600
-58% -$12.1M ﹤0.01% 1904
2019
Q4 		$23M Buy
212,800
+11,300
+6% +$1.21M ﹤0.01% 1478
2019
Q3 		$19.7M Sell
201,500
-30,000
-13% -$3.38M ﹤0.01% 1589
2019
Q2 		$29.2M Buy
231,500
+74,800
+48% +$9.64M 0.01% 1288
2019
Q1 		$21.2M Sell
156,700
-58,000
-27% -$7.21M ﹤0.01% 1504
2018
Q4 		$20.9M Sell
214,700
-25,100
-10% -$2.97M ﹤0.01% 1451
2018
Q3 		$33.3M Buy
239,800
+144,500
+152% +$18.1M 0.01% 1275
2018
Q2 		$11.8M Buy
95,300
+32,400
+52% +$3.79M ﹤0.01% 2005
2018
Q1 		$7.01M Sell
62,900
-180,000
-74% -$21.5M ﹤0.01% 2297
2017
Q4 		$29M Buy
242,900
+10,000
+4% +$1.22M 0.01% 1301
2017
Q3 		$32.2M Sell
232,900
-32,100
-12% -$4.36M 0.01% 1193
2017
Q2 		$32.2M Sell
265,000
-200,000
-43% -$23.3M 0.01% 1150
2017
Q1 		$56.4M Buy
465,000
+265,000
+133% +$34.2M 0.01% 884
2016
Q4 		$24.5M Buy
200,000
+180,000
+900% +$22M 0.01% 1332
2016
Q3 		$2.45M Buy
+20,000
New +$2.57M ﹤0.01% 2681
2015
Q2 		– Sell
-24,400
Closed -$4.23M – 4255
2015
Q1 		$4.23M Buy
+24,400
New +$4.42M ﹤0.01% 2464

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

JP Morgan Chase's ALXN Position: Q3 2021 in Review

JP Morgan Chase sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,748,795 shares — an estimated $321M sold.

JP Morgan Chase first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $1.21B in Q4 2014. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • JP Morgan Chase reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • JP Morgan Chase sold 1,748,795 Alexion Pharmaceuticals shares in Q3 2021, an estimated $321M.
  • JP Morgan Chase first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • JP Morgan Chase's Alexion Pharmaceuticals position peaked at $1.21B in Q4 2014.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on JP Morgan Chase's 13F filing for Q3 2021, filed 12 Nov 2021.